8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 16, 2026·SEC
CytomX Therapeutics, Inc.(CTMX)Earnings, Financials & Key Ratios
CTMX•NASDAQ
$3.74
Price updated Jun 30, 2026
AboutCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Show more
- Revenue$76M-44.8%
- EBITDA-$21M-178.4%
- Net Income-$17M-154.5%
- EPS (Diluted)-0.15-139.5%
- Gross Margin100%
- EBITDA Margin-27.54%-242.1%
- Operating Margin-29.35%-262.2%
- Net Margin-22.79%-198.8%
- ROE-35.25%
CTMX Price & Volume
CytomX Therapeutics, Inc. (CTMX) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependence Drives Volatile Revenue Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical liquidity and dilution
Key Thesis Takeaways
- CytomX Therapeutics faces a precarious outlook as its reliance on lumpy, milestone-driven revenue from pharmaceutical partners fails to offset the high fixed costs of its Probody platform development.
- The company's financial stability is increasingly threatened by a rapid depletion of cash reserves and a diminishing backlog of deferred revenue, which fell from $160.5 million in 2024Q2 to $28.5 million by 2025Q4.
- Investors should monitor the firm's ability to secure new partnerships or capital, as the current burn rate and lack of self-sustaining commercial products suggest significant dilution or liquidity risks remain imminent.
Verdict Logic
the company's cash position of $12.7 million as of 2025Q4 is insufficient to support its ongoing R&D burn rate, which resulted in a $25.5 million free cash flow deficit in 2026Q1.
CTMX Growth Metrics
CytomX Therapeutics, Inc. (CTMX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years25.74%
5 Years2.18%
3 Years12.75%
TTM-75.91%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-242.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-172.2%
Return on Capital
10 Years-21.63%
5 Years-15.05%
3 Years7.19%
Last Year-32.01%
CTMX Recent Earnings
CytomX Therapeutics, Inc. (CTMX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.10+28.6%
$0.14
Rev
$10M+119.1%
$5M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.22-175.0%
$0.08
Rev
$661,000-91.0%
$7M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.09-82.5%
$0.05
Rev
$6M-18.6%
$7M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.00+98.1%
$0.06
Rev
$19M+2.1%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.10vs $0.14+28.6% | $10Mvs $5M+119.1% |
| Q2 2026 | Mar 16, 2026 | $0.22vs $0.08-175.0% | $661,000vs $7M-91.0% |
| Q4 2025 | Nov 6, 2025 | $0.09vs $0.05-82.5% | $6Mvs $7M-18.6% |
| Q3 2025 | Aug 7, 2025 | $0.00vs $0.06+98.1% | $19Mvs $18M+2.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for CytomX Therapeutics, Inc. (CTMX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.74 | $601.48M | -24.93 | -44.82% | -22.79% | -35.25% | — | |
| $38.51 | $7.91B | -13.90 | — | — | -68.16% | — | |
| $31.08 | $3.13B | -9.45 | -4.26% | -156.36% | -68.97% | — | |
| $8.19 | $416.87M | 13.43 | -0.91% | 10.73% | 20.37% | — | |
| $1.10 | $4.88M | -0.17 | — | — | -729.89% | — | |
| $3.15 | $131.17M | -926.47 | 10.37% | 52.16% | — | — |
Compare CTMX vs Peers
CytomX Therapeutics, Inc. (CTMX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTMX SEC Filings & Documents
CytomX Therapeutics, Inc. (CTMX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CTMX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTMX Frequently Asked Questions
CytomX Therapeutics, Inc. (CTMX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is CytomX Therapeutics, Inc.'s revenue?
CytomX Therapeutics, Inc. (CTMX) reported $35.5M in revenue for fiscal year 2025. This represents a 3902% increase from $0.9M in 2013.
How fast is CytomX Therapeutics, Inc. growing?
CytomX Therapeutics, Inc. (CTMX) saw revenue decline by 44.8% over the past year.
Is CTMX profitable?
CytomX Therapeutics, Inc. (CTMX) reported a net loss of $59.1M for fiscal year 2025.
Dividend & Returns
What is CTMX's return on equity?
CytomX Therapeutics, Inc. (CTMX) has a return on equity (ROE) of -35.2%. Negative ROE indicates the company is unprofitable.
What is CytomX Therapeutics, Inc.'s free cash flow?
CytomX Therapeutics, Inc. (CTMX) had negative free cash flow of $80.2M in fiscal year 2025, likely due to heavy capital investments.